Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Lenvatinib in Recurrent Hepatocellular Carcinoma After Liver Transplantation

NCT05103904 is registered in ClinicalTrials.gov with Emory University as lead sponsor.

NCT NCT05103904
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05103904 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Lenvatinib in Recurrent Hepatocellular Carcinoma After Liver Transplantation
Lead sponsor
Emory University
Phase
Phase 2
Overall status
Terminated
Start date
April 19, 2022
Completion date
May 9, 2025
Enrollment
3 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

recurrent hepatocellular carcinoma, stage iii hepatocellular carcinoma ajcc v8, stage iiia hepatocellular carcinoma ajcc v8, stage iiib hepatocellular carcinoma ajcc v8, stage iv hepatocellular carcinoma ajcc v8, stage iva hepatocellular carcinoma ajcc v8, stage ivb hepatocellular carcinoma ajcc v8, unresectable hepatocellular carcinoma